SNGX Novinky na Forexu
Soligenix Says FDA Grants Type A Meeting Regarding New Drug Application For HyBryte
Biopharmaceutical company Soligenix, Inc. (SNGX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file (RTF) letter previously issued regarding the Company's new drug application (NDA) for HyBryte (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer.
RTTNews
|
Před 700 dny
